Search

Search Constraints

You searched for: Author/Creator Jädersten, Martin

Search Results

2. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. Issue 8 (3rd July 2021)

3. Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation. Issue 3 (23rd February 2022)

4. Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin‐23. (8th October 2020)

5. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study. (5th June 2020)

6. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register. (29th April 2018)

7. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. (17th May 2022)

8. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial. (18th August 2022)